Survey Conducted Among Early Breast Cancer Patients Treated With Arimidex for Evaluation of Treatment Adherence
ARIADNE
Survey and Follow-up of the Treatment Adherence and Medication Habits of Early Breast Cancer Patients on Adjuvant Hormonal Therapy With the Aromatase Inhibitor Arimidex
1 other identifier
observational
1,077
1 country
25
Brief Summary
The aim of this study is to assess the patient's perception about and willingness to take his or her medication and the influencing factors interfering with taking medication.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2010
25 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2010
CompletedFirst Submitted
Initial submission to the registry
March 4, 2010
CompletedFirst Posted
Study publicly available on registry
March 5, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2011
CompletedNovember 16, 2011
November 1, 2011
1.6 years
March 4, 2010
November 15, 2011
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Percent of patients remaining adherent to therapy with Arimidex
Every 3 months
Secondary Outcomes (1)
Questionnaire for factors influencing adherence
Every 3 months
Eligibility Criteria
Early breast cancer patients on adjuvant aromatase inhibitor
You may qualify if:
- Early breast cancer
- Post menopausal
- Adjuvant hormonal Arimidex therapy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (25)
Research Site
Balatonföldvár, Hungary
Research Site
Békéscsaba, Hungary
Research Site
Budapest, Hungary
Research Site
Debrecen, Hungary
Research Site
Dombóvár, Hungary
Research Site
Gyöngyös, Hungary
Research Site
Győr, Hungary
Research Site
Gyula, Hungary
Research Site
Kaposvár, Hungary
Research Site
Kecskemét, Hungary
Research Site
Miskolc, Hungary
Research Site
Mosdós, Hungary
Research Site
Nagyatád, Hungary
Research Site
Nyíregyháza, Hungary
Research Site
Orfű, Hungary
Research Site
Pápa, Hungary
Research Site
Pécs, Hungary
Research Site
Szeged, Hungary
Research Site
Szekszárd, Hungary
Research Site
Szentes, Hungary
Research Site
Székesfehérvár, Hungary
Research Site
Szombathely, Hungary
Research Site
Veszprém, Hungary
Research Site
Zalaegerszeg, Hungary
Research Site
Zirc, Hungary
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Zsolt Horvath, M.D., Ph.D.
Hungarian National Institute of Oncology
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 4, 2010
First Posted
March 5, 2010
Study Start
March 1, 2010
Primary Completion
October 1, 2011
Study Completion
October 1, 2011
Last Updated
November 16, 2011
Record last verified: 2011-11